{"nctId":"NCT00818324","briefTitle":"Long Term Administration Study of OPC-12759 Ophthalmic Suspension","startDateStruct":{"date":"2009-01"},"conditions":["Dry Eye Syndromes"],"count":154,"armGroups":[{"label":"OPC-12759 Ophthalmic suspension","type":"EXPERIMENTAL","interventionNames":["Drug: OPC-12759 Ophthalmic suspension"]}],"interventions":[{"name":"OPC-12759 Ophthalmic suspension","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Out patient;\n2. Ocular discomfort severity is moderate to severe;\n3. Corneal-conjunctival damage is moderate to severe;\n4. Unanesthetized Schirmer's test score of 5mm/5minutes or less,or tear breakup time is 5 seconds or less;\n5. Best corrected visual acuity of 0.2 or better in both eyes.\n\nExclusion Criteria:\n\n1. Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis scicca;\n2. Ocular hypertention patient or glaucoma patient with ophthalmic solution;\n3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study;\n4. Anticipated use of contact lens during the study;\n5. Patient with punctal plug;\n6. Any history of ocular surgery within 12 months;\n7. Female patients who are pregnant, possibly pregnant or breast feeding;\n8. Known hypersensitivity to any component of the study drug or procedual medications;\n9. Receipt of any investigational product within 4 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (CFB) in Fluorescein Corneal Staining (FCS) Score","description":"FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. Baseline scores and those obtained at each examination time point were compared (paired t-test).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"2.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline (CFB) in Lissamine Green Conjunctival Staining (LGCS) Score","description":"LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctiva was divided into 6 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-18). 0 is better. Baseline scores and those obtained at each examination time point were compared (paired t-test).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"3.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":154},"commonTop":["Nasopharyngitis","Dysgeusia (bitter taste)","Conjunctival haemorrhage","Conjunctivitis allergic","Trichiasis"]}}}